Kira Gritsman

Thank you, Julio!

Happy to contribute to this exciting project just published in @nature.com led by the amazing Shoichiro Takeishi in a fantastic collaboration with @steidluli.bsky.social - check out this thread 🩸 🧬

Senate Appropriations Committee Approves Defense and Labor, Health and Human Services, and Education Bills | United States Senate Committee on Appropriations United States Senate Committee on Appropriations

Glimmer of hope: the Senate Labor, Health and Human Services Subcommittee just voted, 26 to 3, to reject the administration’s proposed cuts & instead recommend a $400 million increase to the NIH budget. The House LHHS Subcommittee convenes in September
www.appropriations.senate.gov/news/minorit...
🧪

So impressed at the increased support the American Society of Hematology is planning for trainees and early-career investigators!! At some point, someone invested in us. Now it’s our turn. #Fight4Hematology and secure the future of hematology research. Donate! #hemesky www.hematology.org/foundation

Interested in a mentor to guide your career in malignant hematology? Apply for the ASH’s new Mentorship Program, and grow your network! Deadline: Sept 26. Apply today! 🔗 https://bit.ly/3IPWjMA

Interested in becoming a mentor? Sign up today: https://bit.ly/3U5tm1t

#HemeSky

The Myeloid Workshop is back in ASH! Please contact the organizers if you have an exciting story that will not be out by December they are: Zuzana Tothova ,
@ernstlaboratory.bsky.social
@steidluli.bsky.social
@ericpietras.bsky.social
@kathrinbernt.bsky.social
@gritsmanlab.bsky.social

Thank you

Check out our new preprint on an epigenetic resistance mechanism to PI3 kinase inhibition in AML and a new combination therapy with an EZH1/2 inhibitor that depletes leukemic stem cells! Great effort by @thehematopoet and the whole team

Thanks Adrienne!

So excited that our collaboration with the Shechter lab on a new targetable PTM -glutamylation- on NPM1c in AML is now on BioRxiv! Team effort led by @alexkschurer.bsky.social and @humaira2204.bsky.social! 🧪🩸

#NIHfunding cuts have resulted in stalled research. In response, ASH is expanding its Bridge Grant Program with $150K in awards to support critical research by members. Donate to support #hematology researchers and help ensure innovative research continues: https://bit.ly/41LFwjD

#HemeSky #MedSky

If you have applied to an R01 or equivalent, please check out the new eligibility. #hematology #medsky #phdsky #scisky #science

Experts Call NIH Budget Cuts an 'Apocalypse' for Science The reductions target indirect costs that cover administrative and equipment costs.

I have been talking to the media, Time, Fortune, NBC, etc., to explain how the onslaught on science and NIH will impact the health of all Americans. Everyone knows someone who has cancer, heart disease, or depression. Spread the word about how cutting science impacts all.
time.com/7216299/nih-...

📢 Support federal research funding!

As the new Administration acts & Congress finalizes FY25 funding, lawmakers need to hear from you. Share your stories of how funding & policies impact #hematology patients & research.

Take action! bit.ly/4b2bj43

#Fight4Hematology #HemeSky #BloodSky

Calling all aspiring hematologists in med school — don’t leave research funding on the table! 💰

✨ HIP Medical Student Award

✨ HONORS Award

✨ Physician-Scientist Award

Learn more: https://bit.ly/4hexNk7. Your application is due on Feb. 14!

#ASHTrainee #HemeSky #BloodSky #Hematology

Congratulations to all the new ASH Scholars!

Congrats Courtney!

Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications - Current Hematologic Malignancy Reports Purpose of Review More than a decade following the discovery of Calreticulin (CALR) mutations as drivers of myeloproliferative neoplasms (MPN), advances in the understanding of CALR-mutant MPN continu...

Delighted to share our #hematology review article on mutant calreticulin in #MPN
Congrats to co-authors Drs. Mifra Faiz, Merle Riedemann & Jonas Jutzi. We hope it’s a useful resource, link below! @stanforddeptmed.bsky.social
link.springer.com/article/10.1...

Targeting the CD74 signaling axis suppresses inflammation and rescues defective hematopoiesis in RUNX1-familial platelet disorder CD74 signaling drives inflammation and differentiation defects in hematopoietic stem and progenitor cells in RUNX1-familial platelet disorder.

Inflammation plays a key role in RUNX1-FPD pathogenesis. Dr. Anupriya Agarwal & her team at @ohsunews.bsky.social found targeting CD74 signaling, mTOR & JAK1/2 pathways could prevent disease progression. Incredible work by an RRP-EdwardPEvansFdn FIRE grant recipient! www.science.org/doi/10.1126/...

Stanford #Hematology is recruiting! #ASH24 attendees, pls reach out to me if interested! 👇🏽@stanforddeptmed.bsky.social

Excited for this workshop this afternoon and grateful to the organizers Christina Glytsou, Panos Ntziachristos, & Dan Starczynowski for the opportunity to speak in the session alongside @gritsmanlab.bsky.social & Marek Mraz! #ASH24 #hemesky @ash-hematology.bsky.social
ash.confex.com/ash/2024/web...

So sad I am missing #ASH2024 But if you’re there early enough be sure to check out the wonderful @gritsmanlab.bsky.social present exciting updates from my work at the therapy resistance workshop on Friday! 2-5pm in SDCC room 33!

Check out our new review by the amazing @alexkschurer.bsky.social and @thehematopoet.bsky.social on chromatin modifiers in AML! Just in time for the first menin inhibitor FDA approval! 🧪🩸

Yes!

Women are under-represented at senior levels in #academia globally, & across all #science 🧪 disciplines, as shown by these "scissor-shaped curves" ✂️

So how can we ever achieve #gender #equality?

We discuss various strategies in this #Cell Commentary

#WomeninSTEM

www.cell.com/cell/fulltex...
🧵 1/

I’ll be there!

So cool!

Thanks for making this. Can you add me please?

Big day for our field! 🎉

Genotype-immunophenotype relationships in NPM1-mutant AML clonal evolution uncovered by single cell multiomic analysis Acute myeloid leukemia (AML) is a multi-clonal disease, existing as a milieu of clones with unique but related genotypes as initiating clones acquire subsequent mutations. However, bulk sequencing can...

First manuscript from Linde Miles Lab at CCHMC looking at clonal evolution in NPM1-mut AML at single cell resolution. Check out the pre-print here: www.biorxiv.org/content/10.1...